Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
Becton Dickinson & Co. (BDX) Form 144 shows a proposed sale of 58 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $10,474.22 and an approximate sale date of 09/26/2025 on the NYSE. The shares were acquired as Restricted Stock Units on 08/20/2025. The filing also discloses a prior 10b5-1 sale of 57 shares on 08/22/2025 with gross proceeds of $11,285.43. The form lists total shares outstanding as 286,627,469. Several filer contact fields and issuer identification fields are blank in the provided content.
Becton, Dickinson and Company filed an 8-K reporting a material event: the company entered into a Third Amended and Restated Credit Agreement dated September 16, 2025 among Becton, Dickinson and Company, other parties to the agreement, and Citibank, N.A. as administrative agent. The filing identifies the credit agreement as Exhibit 10.1 and includes Inline XBRL interactive data on the cover page. The report also reiterates the company’s registered securities, including its common stock (BDX) and several listed note series. The filing provides the existence and counterparty for the amended credit facility but does not disclose the agreement’s financial terms, covenants, maturity, or commitments within the provided text.
Claire Fraser, a director of Becton, Dickinson and Company (BDX), reported a sale of 917 shares of BDX common stock on 09/10/2025 at a reported price of $187.50 per share. After the sale, the reporting person beneficially owned 22,226 shares in a direct ownership form. The Form 4 was signed by Donna Kalazdy by power of attorney on 09/11/2025.
Becton, Dickinson and Co. (BDX) Form 144 shows a proposed sale of 917 common shares through Merrill Lynch on 09/10/2025, with an aggregate market value of $171,862.50. The filer acquired these shares as a stock bonus on 01/23/2025 from Claire Marie Fraser and paid by stock bonus on the same date. The filing also discloses a recent sale of 863 shares on 08/08/2025 for gross proceeds of $165,879.90. Outstanding shares are listed as 286,627,469, making these transactions a very small fraction of total shares outstanding.
Christopher DelOrefice, EVP & Chief Financial Officer of Becton, Dickinson and Company (BDX), reported a transaction on 09/01/2025. The Form 4 shows 278 shares of BDX common stock were disposed under transaction code "F" with a reported price of $0. The explanatory note states these shares were withheld to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units. After this withholding, Mr. DelOrefice beneficially owns 21,221 shares directly. The filing was signed by Donna Kalazdy by power of attorney on 09/02/2025.
Becton, Dickinson and Company insider Richard Byrd, serving as EVP & President Interventional, reported a transaction dated 09/01/2025 involving 216 shares of BDX common stock that were disposed at a reported price of $0. The filing shows 6,736 shares owned following the transaction. The explanatory note states these 216 shares were withheld to satisfy withholding taxes related to the vesting of previously granted restricted stock units. The Form 4 was signed by a power of attorney on 09/02/2025.
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson & Co. (BDX), reported the sale of 57 shares of common stock on 08/22/2025 at a price of $197.99 per share, leaving him with 8,360 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted on August 2, 2024, indicating a prearranged, compliant insider trading plan.
Becton, Dickinson and Co. (BDX) filed a Form 144 reporting a proposed sale of 57 common shares through Morgan Stanley Smith Barney LLC. The filing states the shares were acquired as restricted stock units (RSUs) from the issuer on 08/20/2025 and the proposed approximate sale date is 08/22/2025. The filing shows an aggregate market value of $11,207.91 for the 57 shares and reports 286,627,469 shares outstanding. No securities of the issuer were reported sold by the filer in the past three months.
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson and Company (BDX), reported a non-derivative disposition of 773 shares of BDX common stock on 08/20/2025. The filing uses transaction code F, and the explanatory note states these shares were withheld to satisfy tax withholding upon vesting of previously granted restricted stock units, so the reported price is shown as $0. After the withholding, Mr. Feld beneficially owned 8,417 shares directly. The Form 4 was signed by Donna Kalazdy by power of attorney on 08/22/2025.
Becton, Dickinson and Co. is reported as having 16,178,519 shares beneficially owned by T. Rowe Price Investment Management, Inc., representing 5.6% of the outstanding common stock. The filing shows T. Rowe Price holds sole voting power over 15,106,743 shares and sole dispositive power over 16,178,519 shares, and classifies the filer as an investment adviser. The filing includes a written certification that the shares are held in the ordinary course of business and are not held to change or influence control of the company.
This Schedule 13G discloses a passive, greater-than-5%-ownership stake in BDX by a large institutional investment adviser, providing investors clarity on a significant passive holder and the exact voting and dispositive powers reported.